CLINICAL_TRIALS
trial_result
· 2018-05-11
Clinical Trial Update: Study of Safety and Tolerability of VLX600, an Iron Chelator, in Patients With Refractory Advanced Solid Tumors [Phase 1]
Summary
A Phase 1 study evaluating the safety and tolerability of VLX600 in patients with refractory advanced solid tumors has been terminated.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Vivolux AB | Conditions: Refractory Cancer | Phase 1 | Status: TERMINATED